Table 3.

Demographics and clinical information for patients with of juvenile dermatomyositis.

Sex	10 female, 2 male
Average age in years (range)	9.9 (3.4–16.9)
Average oral prednisone dose at the time of follow up sample in mg/kg/day (range)	0.3 (0.08–0.7)
	*6 patients were also receiving weekly IV solumedrol pulses at the time of follow up sample (range 1–29.5 mg/kg)
Average duration of prednisone therapy in months from baseline to follow up (range)	6.9 (0.62–16.33)
Concomitant immunomodulatory medications at baseline (n = 12 baseline)	1 mycophenylate mofetil (MMF)
Concomitant immunomodulatory medications at follow up (n = 12 follow up)	10 patients:
	1 IV immunoglobulin (IVIG), cyclosporine, MMF, and hydroxychloroquine; 1 IVIG, cyclosporine,
	and MMF; 2 MMF;
	1 cyclosporine and MMF; 2 methotrexate;
	2 methotrexate and hydroxychloroquine;
	1 methotrexate and MMF
Average DAS Baseline (range)	Skin: 5.6 (2–7)
	Muscle: 3.1 (1–9)
	Total: 8.7 (6–16)
Average DAS Follow up (range)	Skin: 3.3 (0–7)
	Muscle: 1.7 (0–6)
	Total: 5 (0–14)

Abbreviations: DAS = Disease Activity Score.

^*Range of DAS for skin is 0–9, muscle 0–11 and total 0–20.